LRAD Corporation (LRAD): I'm more like a guppy, but yes I bought...

rayank · 2017-02-16T13:44:06.2070000Z

I'm more like a guppy, but yes I bought back in yesterday after 4 years. So now where are those whales? LOL

Play Episode

6min

Proactive - Interviews for investors

Zynex Medical champions noninvasive, non-addictive pain management with NexWave

Zynex Medical Executive Vice President of Sales Steve Fox joined Steve Darling from Proactive to discuss the company’s commitment to noninvasive, non-addictive at-home pain management through its flagship device, NexWave. Fox highlighted how Zynex Medical is tackling the opioid crisis by providing alternative pain solutions that empower both healthcare providers and patients. The NexWave device integrates three key modalities—TENS (Transcutaneous Electrical Nerve Stimulation), IFC (Interferential Current), and NMES (Neuromuscular Electrical Stimulation)—making it a versatile tool for post-operative recovery and long-term pain management. “Most providers are really on board with a device like this because it’s very universal,” Fox explained. A crucial aspect of Zynex’s strategy is education, with nearly 300 sales representatives across the U.S. working to inform healthcare providers about alternatives to opioid prescriptions. While the company’s focus remains on the domestic market, Fox noted significant untapped potential within the United States. Fox also spoke about Zynex’s strong internal culture, emphasizing the team’s alignment around a shared mission. “It’s our mission to provide an at-home pain management treatment option that’s noninvasive, non-addictive. That won’t change,” he said, highlighting the passion and unity that continue to drive the company’s growth. #proactiveinvestors #nasdaq #zyxi #zynexinc #NexWave #PainManagement #OpioidAlternative #MedicalDevices #NonInvasiveTherapy #NMES #TENS #HealthcareInnovation #ProactiveInvestors

Proactive - Interviews for investors

Kodal Minerals nears completion at Bougouni Lithium project, prepares for exports

Kodal Minerals PLC (AIM:KOD) CEO Bernard Aylward takes Proactive's Stephen Gunnion through the company's latest update on its Bougouni lithium project in Mali, where construction is nearly complete and preparations for export are underway. Aylward shared that the optimisation and ramp-up phase of the processing plant has been going well, with over 11,000 tonnes of lithium concentrate already stockpiled and ready for export. "We've been making some adjustments as we go through this process and some improvements to the feed into the crusher... achieving a good product," he said. He noted that the company expects to reach nameplate capacity within the next couple of months, pending a final review and approval by the construction team. Kodal is also progressing steadily on the mining front, with a good run-of-mine (ROM) stockpile in place. The interview highlighted that the mining license transfer process is still ongoing, though Kodal has completed all compliance steps and is now awaiting sign-off from the Committee of Ministers and the President of Mali. Once this is finalised, the company will move forward with export permits and begin shipping product. Visit Proactive’s YouTube channel for more company updates. Don’t forget to like this video, subscribe, and turn on notifications to stay up to date. #KodalMinerals #Lithium #BougouniProject #MiningNews #BatteryMetals #MaliMining #ResourceDevelopment #LithiumProduction #MineralExploration #CriticalMinerals

Proactive - Interviews for investors

Tamboran Resources boosts NT gas supply with Arafura deal

Tamboran Resources Ltd CEO Joel Riddle talked with Proactive about the company's newly signed letter of intent (LOI) with Arafura Resources Ltd to supply gas from the Beetaloo Basin. Riddle explained that both companies are based in the Northern Territory, and the agreement supports local strategic projects by providing 25 terajoules (TJs) per day to Arafura's critical minerals project. The agreement aligns with Tamboran’s strategy of prioritising Northern Territory gas use. “We’re a Northern Territory company. We’ve been focused on appraising the Beetaloo Basin now for all 12 years I’ve been in my job,” Riddle said, highlighting the company’s long-term commitment to the region. Riddle also pointed out the environmental edge of Beetaloo Basin gas, which has a CO2 content of about 3%, significantly lower than the 15–20% typically found in other Australian basins. He said supplying this low-carbon gas to the East Coast would help reduce emissions by displacing higher-carbon alternatives. Discussing supply capacity, Riddle compared the Beetaloo to the Marcellus Shale in the US, noting it could provide enough gas to support the East Coast for “hundreds of years”. Tamboran plans to bring 40 TJs per day online in the first half of next year under an existing 15-year agreement with the NT Government. The Arafura deal will add a further 25 TJs daily. Riddle said work is underway with pipeline partner APA to ensure infrastructure capacity. The company aims to finalise a binding gas sales agreement with Arafura soon. Watch the full interview to hear how Tamboran is positioning Beetaloo gas as a key part of the East Coast supply solution, while supporting Northern Territory industry. 👉 For more interviews and updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and hit the notification bell for future content. #TamboranResources #BeetalooBasin #LowCarbonGas #GasSupply #ArafuraResources #EastCoastEnergy #NorthernTerritory #CriticalMiner

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Followers	75
Posts	10296
Boards Moderated	1
Alias Born	11/22/2004

Volume:	-
Day Range:
Bid:	3.31
Ask:	3.39
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

LRAD Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free